Literature DB >> 31076279

Human mitochondrial DNA diseases and Drosophila models.

Zhe Chen1, Fan Zhang2, Hong Xu3.   

Abstract

Mutations that disrupt the mitochondrial genome cause a number of human diseases whose phenotypic presentation varies widely among tissues and individuals. This variability owes in part to the unconventional genetics of mitochondrial DNA (mtDNA), which includes polyploidy, maternal inheritance and dependence on nuclear-encoded factors. The recent development of genetic tools for manipulating mitochondrial genome in Drosophila melanogaster renders this powerful model organism an attractive alternative to mammalian systems for understanding mtDNA-related diseases. In this review, we summarize mtDNA genetics and human mtDNA-related diseases. We highlight existing Drosophila models of mtDNA mutations and discuss their potential use in advancing our knowledge of mitochondrial biology and in modeling human mitochondrial disorders. We also discuss the potential and present challenges of gene therapy for the future treatment of mtDNA diseases. Published by Elsevier Ltd.

Entities:  

Keywords:  Drosophila model; Mitochondrial DNA; mtDNA disease; mtDNA genetics

Mesh:

Substances:

Year:  2019        PMID: 31076279     DOI: 10.1016/j.jgg.2019.03.009

Source DB:  PubMed          Journal:  J Genet Genomics        ISSN: 1673-8527            Impact factor:   4.275


  2 in total

1.  The PPR domain of mitochondrial RNA polymerase is an exoribonuclease required for mtDNA replication in Drosophila melanogaster.

Authors:  Yi Liu; Zhe Chen; Zong-Heng Wang; Katherine M Delaney; Juanjie Tang; Mehdi Pirooznia; Duck-Yeon Lee; Ilker Tunc; Yuesheng Li; Hong Xu
Journal:  Nat Cell Biol       Date:  2022-04-21       Impact factor: 28.213

Review 2.  Mitochondria Dysfunction in Frontotemporal Dementia/Amyotrophic Lateral Sclerosis: Lessons From Drosophila Models.

Authors:  Sharifah Anoar; Nathaniel S Woodling; Teresa Niccoli
Journal:  Front Neurosci       Date:  2021-11-24       Impact factor: 4.677

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.